Overview

A Safety and Efficacy Study of 552-02 in Subjects With Dry Mouth Associated With Sjogren's Syndrome

Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
This clinical study is to determine whether daily administration of a formulation of 552-02 improves the dry mouth condition in subjects with primary Sjögren's syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
Parion Sciences